注射

Table 1 medical packaging materials, containers, scope of pharmaceutical packaging materials, containers, in the form of the name preparation notes plastic bottle kalidehydroandrogropholidi = 50ml material with PP, LDPE Infusion bags, kalidehydroandrogropholidi = 50ml material is PVC, polyalkene glass infusion bottle 50ml clorsulon = injection bottle kalidehydroandrogropholidi 50ml, kalidehydroandrogropholidi = 50ml-molded, control of glass bottle kalidehydroandrogropholidi kalidehydroandrogropholidi 50ml kalidehydroandrogropholidi 50ml ampule medical plastic bottle of tablets, capsules, tablets, colour.10pills glass ampoules, pills and capsules, syrup, oral solution, nanosuspensions, immunoembolization, tincture, linimentum, lotio hard PVC medicinal Tablet and capsule-plastic blister packaging PVC/PE/PVDC medicinal compound hard Tablet and capsule-plastic blister packaging Composite PVC/PVDC medicinal Tablet and capsule hard-plastic blister packaging cold metal forming hard medicinal compound tablets, capsules, suppository materials have nylon/aluminium/PVC double aluminum packaging Tablet and capsule PVC/hard LDPE medicinal compound tablets, capsules, suppository glass bottle ciinincal ciinincal ciinincal plastic bottle medicinal ciinincal medicinal eardrops plastic bottle eardrops medicinal nasal drops plastic bottle nose drops for external use liquid medicinal plastic bottle tincture, linimentum, lotio koufuye of medicinal plastic bottle syrup, oral solution, nanosuspensions, immunoembolization glass control oral bottle syrup, oral solution, nanosuspensions, immunoembolization packaging for medicine bag laminating film, puivis bletillae, feian and Tablet foil Tablet and capsule of unguentum Al fighting、smoke aluminium pipe, oculentum, puivis bletillae, Tin aerosolon, nabulization materials have aluminum, plastic valve pyritionate, nabulization stopple kalidehydroandrogropholidi 50ml, 50ml clorsulon = material bromide, CIIR synthesis of oprene 50ml clorsulon = gasket aluminium caps combination Cap koufuye falchion, kalidehydroandrogropholidi 50ml, 50ml prestrain kalidehydroandrogropholidi = potting needle kalidehydroandrogropholidi 50ml desiccant tablets, capsules, pills and aluminium bottles vinpocetione polyethylene film and bag vinpocetione b, package management and standards on the management of the drug packaging mainly has two modes: a mode of government management, such as Singapore, Indonesia adopted a market access system, United States, Canada, the European Union through the implementation of the medicine on the packaging of the strict management, that is, the drug registration, declare to use medical packaging of related materials; Government departments on the packaging manufacturer production system to carry out spot checks.

表1 药品包装材料、容器适用的范围药用包装材料、容器名称制剂形式备注塑料输液瓶注射剂≥50ml 材料有PP、LDPE 输液膜、袋注射剂≥50ml 材料有PVC、聚烯烃玻璃输液瓶注射剂≥50ml 冻干注射剂瓶注射剂0ml、注射剂≥50ml 模制、管制玻璃注射剂瓶注射剂0ml 安瓿注射剂0ml 口服固体药用塑料瓶片剂、胶囊、丸剂玻璃药瓶片剂、胶囊、丸剂、糖浆剂、口服溶液剂、混悬剂、乳剂、酊剂、搽剂、洗剂 PVC药用硬片片剂、胶囊铝塑泡罩包装 PVC/PE/PVDC药用复合硬片片剂、胶囊铝塑泡罩包装 PVC/PVDC药用复合硬片片剂、胶囊铝塑泡罩包装冷冲压成型药用复合硬片片剂、胶囊、栓剂材料有尼龙/铝/聚氯乙烯双铝包装片剂、胶囊 PVC/LDPE药用复合硬片片剂、胶囊、栓剂玻璃滴眼剂瓶滴眼剂药用滴眼剂塑料瓶滴眼剂药用滴耳剂塑料瓶滴耳剂药用滴鼻剂塑料瓶滴鼻剂外用液体药用塑料瓶酊剂、搽剂、洗剂口服液体药用塑料瓶糖浆剂、口服溶液剂、混悬剂、乳剂玻璃管制口服液瓶糖浆剂、口服溶液剂、混悬剂、乳剂药品包装用复合膜、袋散剂、颗粒剂、片剂药品包装用铝箔片剂、胶囊铝管、铝塑管软膏、眼膏剂、散剂、罐气雾剂、喷雾剂材料有铝、塑料阀门气雾剂、喷雾剂胶塞注射剂0ml、注射剂≥50ml 材料有溴化、氯化丁基橡胶合成聚异戊二烯垫片注射剂≥50ml 铝盖、铝塑组合盖口服液、注射剂0ml、注射剂≥50ml 预灌封注射针注射剂0ml 干燥剂片剂、胶囊、丸剂铝瓶原料药聚乙烯膜、袋原料药二、包装管理及标准各国对药品包装的管理主要有两种模式：一种模式是政府管理，如新加坡、印度尼西亚采取市场准入制的方式，美国、加拿大、欧盟通过对药品的管理实施对药品包装的严格管理即在药品注册时，申报所使用药品包装的相关材料；政府部门对药品包装生产企业的生产体系进行现场检查。

Material and MethodsRA Rabbit Model group: 15 early RA rabbits of the same weight and variety Control group:10 normal rabbits of the same weight and varietyMethods of making RA rabbit model:elect 15 normal rabbits of the same weight and variety, dissolve Ovalbumin in 0.9% sodium chloride solution, to make the solution of 20mg/ml concengtration, blend the same quantity of complete Freund′s Adjuvant equably ,inject the mixed solution into endermic tissue of the rabbit′s scapular section, making the rabbits allergic, inject 1 ml of the mixed solution to one rabbit every time, inject 1 ml of the mixed solution in 5 different places of the rabbit′s scapular section, inject the rabbit one time every week,inject 3 weeks continuously,it turned out to be that the rabbits will be allergic, inject Ovalbumin blent with the 0.9% sodium chloride solution into the knee joint cavity of the rabbits in the fourth week, 5 mg Ovalbumin every knee joint cavity,two knees of every rabbit of the 15 rabbits are both injected,the arthrosis diameter and the exterior temperature of the knees will be added obviously in 24 hours,and they will drop gradually,at the time of the 14th or 21th day, the arthrosis diameter and the exterior temperature of the knees will get to the balance time,the incidence rate of RA is 100%.after the RA model succeeds,it is the early time of RA from the first week to the fourth week,after the fourth week,it is the late time of RA, the cartilage of the femoral condyle and the subchondral bone cortices will be changed unrecoverily.

资料与方法RA模型组：早期RA家兔模型15只，品种及体重接近。对照组：正常家兔10只，品种及体重接近。RA家兔模型制作方法：选取15只成年家兔，体重、品种接近，将卵蛋白溶解于生理盐水，配成浓度为20mg/ml的溶液，与等量完全弗氏佐剂混匀，注入家兔肩胛区皮下致敏，每只家兔每次注射1ml，于肩胛区5个不同区域注射，每周一次，连续注射3周而致敏，第4周向膝关节腔注射卵蛋白生理盐水溶液，每只关节腔注射5mg卵蛋白，15只家兔膝关节全部注射，24h内此关节直径和表面温度大幅度上升，以后缓慢下降，至14～21d达到平台期，发病率达100%。造模成功后第1～4周为早期改变，第4周以后出现不可逆的关节软骨及骨破坏。采用高频超声对RA模型组与对照组的膝关节髌上囊液体厚度、滑膜及股骨髁软骨厚度及软骨下骨皮质的回声情况进行对比观察。结果RA组模型组膝关节髌上囊积液及滑膜的厚度明显厚于对照组，其股骨髁软骨的厚度与对照组相比无明显差异，其软骨下骨皮质与对照组相比无明显改变。

Lots of people think ' Oh, it's like a hypodermic注射用的 needle,' Lao said .

许多人认为'噢，这像一个注射用的针。'

Results On day 7, 15, 30 after injection with exogenous VEGF, the mice in VEGF group were found more renascent blood vessels, splenic corpuscles, central arteries and peripheral lymphatic sheathes in the autotransplanted splenic tissues than the control group, and eventually formed more integral structure of white pulp, marginal zone and red pulp with much less fibrous tissue, while on day 60 there was no significant difference between VEGF group and the control group.

结果术后7、15、30 d注射VEGF组注射VEGF后较对照组的血管数量明显增多；术后60 d注射VEGF组注射VEGF后与对照组各时相点的组织学特征没有明显差别；术后7、15、30 d注射VEGF组KDR面积密度值高于对照组，术后60 d注射VEGF组 KDR面密度值与对照组比较无显著差别；术后7、15、30 d注射 KDR mRNA表达阳性细胞密度高于对照组，术后60 d注射VEGF组 KDR mRNA表达阳性细胞密度与对照组比较没有明显差异。

Rats living over 96h were considered survival. To observe the protective effects of ALR gene on acute liver injury rat, thirty-six rats that were injected peritoneally with 50% CCl4 of 2ml/kg were divided into the flowing 6 group according to doses (50?g/kg and 200?g/kg ) and administration routes of pcDNA3-ALR DNA 4h after CCl4 injection: group 1, model group; group 2, ALR gene of 50μg/kg was injected venally; group 3, ALR gene of 200?

另取36只大鼠按2ml/kg腹腔注射50% CCL4，染毒后4h按不同剂量（50μg/kg 和200μg/kg ）、不同注射途径（尾静脉注射、腹腔注射和联合注射）随机分为六组。1组：模型组，不注射ALR基因； 2组：尾静脉注射ALR基因 50μg/kg； 3组：尾静脉注射ALR基因 200μg/kg； 4组：腹腔注射ALR基因 50μg/kg； 5组：腹腔注射ALR基因 200μg/kg； 6组：联合注射（尾静脉和腹腔各注射ALR 基因100μg/kg）。

This topic intends to set up the animal model of apositia with the function of central inhibition to investigate the pharmacological effect of Shanzha Maiya granula and research the functional mechanism of the Chinese medicines for invigorating spleen to promote digestion in view of braingut petide-appestat.

CLAIRE报道LP50μg/kg单独腹腔注射可以降低大鼠进食量，LP 50μg/kg和8～16μg/kgCCK联合腹腔注射效果更佳，两者联合腹腔注射后与LP单独腹腔注射后大鼠食量比较差异有统计学意义，Scott等报道第三脑室注射LP 7μg/kg和腹腔注射CCK 2μg/kg都有降低食欲的作用。

The local injection of trypsin can be used in clinical practice as a new and effective therapy for snakebite.Our experiments indicate that when a lethal dose of crotalinae snake venom was injected into mice subcutaneously, survival rate increased significantly if a dose of trypin had been injected locally and promptly.

本文提供了一种局部注射胰蛋白酶治疗蛇伤的方法，在给小白鼠皮下注射致死剂量的竹叶青蛇毒后，立即注射胰蛋白酶可提高存活率68％，注射蝮蛇毒后，立即注射胰蛋白酶可提高存活率67％，注射尖吻蝮蛇毒后立即注射胰蛋白酶可提高存活率57％。

Daidzein was micro injected into mediobasal hypothalamus and nucleus ventromedialis thalami of castrated male Goettingen Mini pigs (n=9, 10μl/animal,8pgDA/μl) and plasma LH levels were compared prior and posterior to the treatment.

在去势格丁根小公猪(n =9)下丘脑MBH和VM部位注射大豆黄酮(10 μl/头，8pg/μl)，注射后血浆LH浓度变化呈上升趋势：在MBH部位，注射后 0 。5～ 2h有 4例(4/ 5 )LH水平较注射前升高，1例(1/ 5 )变化不明显(P≤0 。0 5 )，注射 2 。5h后与注射前比较无明显变化；在VM部位，注射后 3例(3/ 4 )升高，1例变化不明显。

Quite a few terminally晚期地,致命地ill patients would often like their doctors to administer lethal drugs注射致命药物 to them to be relieved of suffering; there are also some of their families who would prefer that doctors withdraw any life-prolonging treatment撤销延长生命性质的治疗since there is no hope of effecting an ultimate cure.

相当一部分绝症末期的病人通常想让他们的医生为他们注射致命药物，将他们从痛苦中解救出来。同时，还有一些病人家属向医生提出，撤销延长病人生命性质的治疗，因为对其最终的治疗并不抱什么希望。

The effects and mechanism of GABAergic neurons, NOergic neurons, opioid peptide and cyclic adenosine monophosphate in the nucleus reticularis thalami on sleep-wakefulness cycle of rats and the effects and mechanism of the 5-HTergic nerve fibers project from the nucleus raphes dorsalis to RT on sleep-wakefulness cycle of rats were investigated with the methods of brain stereotaxic, nucleus spile, microinjection and polysomngraphy.1. The effects of GABAergic neurons in RT on sleep-wakefulness cycle of rats1.1 Microinjection of 3-mercaptopropionic acid (3-MP, a kind of glutamate decarboxylase inhibitor) into RT. On the day of microinjection, sleep only decreased a litter. On the second day, sleep marked decreased and wakefulness marked increased. On the third and fourth day, sleep and wakefulness stages resumed to normal.1.2 Microinjection of gamma-amino butyric acid (GABA 1.0μg) into RT enhanced sleep and reduced wakefulness compared with control; while microinjection of L-glutamate (L-Glu, 0.2μg) decreased sleep and increased wakefulness; microinjection of bicuculline (BIC, 1.0μg), a GABAA receptor antagonist, enhanced wakefulness and reduced sleep; microinjection of baclofen (BAC, 1.0μg), GABAB receptor agonist, had the same effects as GABA.2. The effects of NOergic neurons in RT on sleep-wakefulness cycle of rats2.1 Microinjection of L-arginine (L-Arg, 0.5μg) into RT decreased sleep compared with control, but there were on statistaical difference between L-Arg group and control; while microinjection of sodium nitroprusside (SNP, 0.2μg), a NO donor into RT, sleep marked decreased and wakefulness marked increased. Microinjection of nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NNA, 2.0μg) into RT enhanced sleep and reduced wakefulness.2.2 After simultaneous microinjection of L-NNA (2.0μg) and SNP (0.2μg) into RT, SNP abolished the sleep-promoting effect of L-NNA compared with L-NNA group; after simultaneous microinjection of L-NNA (2.0μg) and L-Arg(0.5μg) into RT, we found that L-NNA could not blocked the wakefulness-promoting effect of L-Arg.3. The effects of opioid peptide in RT on sleep-wakefulness cycle of rats3.1 Microinjection of morphine sulfate (MOR, 1.0μg) into RT increased wakefulness and decreased sleep compared with control; while microinjection of naloxone hydrochloride (NAL, 1.0μg), the antagonist of opiate receptors, into RT, enhanced sleep and reduced wakefulness.3.2 After simultaneous microinjection of MOR (1.0μg) and NAL (1.0μg) into RT, the wakefulness-promoting effect of MOR and the sleep-promoting effect of NAL were not observed compared with control.4. The effects of cAMP in RT on sleep-wakefulness cycle of rats Microinjection of cAMP (1.0μg) into RT increased sleep and decreased wakefulness compared with control; microinjection of methylene blue (MB,1.0μg) into RT enhanced sleep and reduced wakefulness compared with control.5. The effects of the 5-HTergic nerve fibers project from DRN to RT on sleep-wakefulness cycle of rats5.1 When L-Glu (0.2μg) was microinjected into DRN and normal sodium (NS,1.0μg) was microinjected into bilateral RT. We found that sleep was decreased and wakefulness was increased compared with control; when L-Glu (0.2μg) was microinjected into DRN and methysergide (MS,1.0μg), a non-selective 5-HT antagonist, was microinjected into bilateral RT, We found that sleep was enhanced and wakefulness was reduced compared with L-Glu group.5.2 When p-chlorophenylalanine (PCPA, 10μg) was microinjected into DRN and NS (1.0μg) was microinjected into bilateral RT, We found that sleep was increased and wakefulness was decreased compared with control; microinjection of 5-hydroxytryptaphan (5-HTP, 1.0μg), which can convert to 5-HT by the enzyme tryptophane hydroxylase and enhance 5-HT into bilateral RT, could block the effect of microinjection of PCPA into DRN on sleep-wakefulness cycle.

本研究采用脑立体定位、核团插管、微量注射、多导睡眠描记等方法，研究丘脑网状核(nucleus reticularis thalami，RT)中γ-氨基丁酸(gamma-amino butyric acid ，GABA)能神经元、一氧化氮(nitrogen monoxidum，NO)能神经元、阿片肽类神经递质、环一磷酸腺苷(cyclic adenosine monophosphate，cAMP)及中缝背核(nucleus raphes dorsalis，DRN)至RT的5-羟色胺(5-hydroxytryptamine，5-HT)能神经纤维投射对大鼠睡眠-觉醒周期的影响及其作用机制。1 RT内GABA能神经元对大鼠睡眠-觉醒周期的影响1.1大鼠RT内微量注射GABA合成关键酶抑制剂3-巯基丙酸(3-MP，5μg)，注射当天睡眠时间略有减少，第二日睡眠时间显著减少，觉醒时间明显增多，第三、四日睡眠和觉醒时间逐渐恢复至正常。1.2大鼠RT内微量注射GABA受体激动剂GABA( 1.0μg)后，与生理盐水组比较，睡眠时间增加，觉醒时间减少；而RT内微量注射L-谷氨酸(glutamic acid， L-Glu， 0.2μg)后，睡眠时间减少，觉醒时间增加；RT内微量注射GABAA受体阻断剂荷包牡丹碱(bicuculline，BIC，1.0μg)后，睡眠时间减少，觉醒时间增加；RT内微量注射GABAB受体激动剂氯苯氨丁酸(baclofen，BAC，1.0μg)后，产生了与GABA相似的促睡眠效果。2 RT内NO能神经元对大鼠睡眠-觉醒周期的影响2.1大鼠RT内微量注射NO的前体L-精氨酸(L-Arg，0.5μg)后，与生理盐水组对比，睡眠时间略有减少，但无显著性意义；而RT内微量注射NO的供体硝普钠(Sodium Nitroprusside，SNP，0.2μg)后可明显增加觉醒时间，缩短睡眠时间；微量注射一氧化氮合酶抑制剂L-硝基精氨酸(L-arginine，L-NNA，2.0μg)后，引起睡眠时间增多，觉醒时间减少。2.2大鼠RT内同时微量注射L-NNA(2.0μg)和SNP(0.2μg)后与L-NNA组比较发现SNP逆转了L-NNA的促睡眠作用；RT内同时微量注射L-NNA(2.0μg)和L-Arg(0.5μg)后，与L-NNA(2.0μg)组比较发现L-Arg可以增加觉醒而缩短睡眠，其促觉醒作用未能被NOS的抑制剂L-NNA所逆转。3 RT内阿片肽对大鼠睡眠-觉醒周期的影响3.1大鼠RT内微量注射硫酸吗啡(morphine sulfate，MOR，1.0μg)后与生理盐水组对比，睡眠时间减少而觉醒时间增加； RT内微量注射阿片肽受体拮抗剂盐酸纳洛酮(naloxone hydrochloride，NAL，1.0μg)后与生理盐水组比较，睡眠时间增加而觉醒时间减少。3.2大鼠RT内同时微量注射MOR(1.0μg)和NAL(1.0μg)后，与生理盐水组对比，原有的MOR促觉醒效果和NAL的促睡眠效果都没有表现。4 RT内环一磷酸腺苷信使对大鼠睡眠-觉醒周期的影响大鼠RT内微量注射cAMP(1.0μg)后与NS(1.0μg)组比较，睡眠时间增多而觉醒时间减少；RT内微量注射亚甲蓝(methylene blue，MB，1.0μg)后，与NS组比较，睡眠时间增多而觉醒时间减少。5中缝背核投射到丘脑网状核的5-羟色胺能神经纤维对大鼠睡眠-觉醒周期的影响5.1大鼠DRN内微量注射L-Glu(0.2μg)，同时在双侧RT内微量注射NS (1.0μg)后，与对照组(DRN和双侧RT注射NS， 0.2μg)比较，睡眠时间减少，觉醒时间增多；大鼠DRN内微量注射L-Glu(0.2μg)，同时在双侧RT内微量注射二甲基麦角新碱(methysergide， MS， 1.0μg )后，与对照组(DRN注射L-Glu 0.2μg，双侧RT注射NS 1.0μg)比较，睡眠时间增多，觉醒时间减少。5.2大鼠DRN内微量注射对氯苯丙氨酸(p-chlorophenylalanine，PCPA，10μg)，同时在双侧RT内微量注射NS (1.0μg)后，与对照组(DRN和双侧RT注射NS， 1.0μg)比较，睡眠时间增多，觉醒时间减少；大鼠DRN内微量注射PCPA(10μg)，产生睡眠增多效应后，在双侧RT内微量注射5-羟色胺酸(5-hydroxytryptaphan ， 5-HTP， 1.0μg )后，与对照组(DRN注射PCPA 10μg，双侧RT注射NS 1.0μg)比较，睡眠时间减少，觉醒时间增多。

In the United States, chronic alcoholism and hepatitis C are the most common ones.

在美国，慢性酒精中毒，肝炎是最常见的。

If you have any questions, you can contact me anytime.

如果有任何问题，你可以随时联系我。